People · Operator
Named in public records as an officer, director or promoter · active 2018–2024 · Pharma, Biotechnology, Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Century Therapeutics, Inc. | — | Pharma | Series D+ | $160.0M | $4.7B | 2021 |
| Graphite Bio, Inc. | — | Biotechnology | Series D+ | $150.7M | $4.9B | 2021 |
| 858 Therapeutics, Inc. | — | Pharmaceuticals | Series B | $65.2M | $177.2M | 2021 |
| Nexo Therapeutics, Inc. | — | Biotechnology | Series C | $60.0M | $994.9M | 2022 |
| Quentis Therapeutics, Inc. | — | Biotechnology | Series B | $22.7M | $780.9M | 2018 |
| Pandion Therapeutics, Inc. | — | Biotechnology | Series B | $21.6M | $857.3M | 2018 |
| Pep2Tango Therapeutics, Inc. | — | Biotechnology | Series B | $16.7M | $108.3M | 2024 |
Carlo Rizzuto at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Carlo Rizzuto on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Ali Behbahani | 2 | 17 |
| Michael Kim | 1 | 14 |
| Jerel Davis | 1 | 13 |
| Amy Schulman | 1 | 11 |
| Alan Crane | 1 | 9 |
| Clare Ozawa | 1 | 8 |
| Eli Casdin | 1 | 6 |
| Bradley J. Bolzon | 1 | 5 |
| Mitchell Mutz | 1 | 5 |
| Vikas Goyal | 1 | 5 |
| Abraham Bassan | 1 | 4 |
| Andrew Phillips | 1 | 3 |
| Michael Foley | 1 | 3 |
| Cynthia Butitta | 1 | 3 |
| Joseph Jimenez | 1 | 3 |
| Juergen Eckhardt | 1 | 3 |
| Michael Aberman | 1 | 2 |
| Perry Karsen | 1 | 2 |
| Josh Lehrer | 1 | 2 |
| Matthew Porteus | 1 | 2 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.